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Overview
In this report, we evaluate and synthesize the
published literature on diagnosis of, and medical
and nonmedical interventions for treatment-
resistant epilepsy. This report was commissioned
upon the request of the Centers for Disease
Control and Prevention and the Social Security
Administration.
Epilepsy is a common, serious neurologic
condition. An International League Against
Epilepsy (ILAE) Commission Report from 1997
estimated the prevalence of active epilepsy as 40
to 100 in 10,000 and the incidence of
unprovoked seizures as 2 to 7 per 10,000.
However, precise estimates of prevalence and
incidence are complicated by differences in the
way investigators define epileptic and
nonepileptic seizures (NES), and by the fact that
prevalence is typically estimated using
retrospective methods.
In addition to the immediate, debilitating
effects of seizures, epilepsy also interferes with
daily activities, and persons with epilepsy may
have to contend with the increased possibility of
accidental injury and even death. Psychiatric
disorders may also be more common in people
with epilepsy.
Persons with epilepsy often have impaired
physical, psychological, and social functioning,
which may lead to economic loss and
diminished quality of life. A survey of 1,023
people with epilepsy published in 2000 showed
that compared to U.S. Census Bureau norms,
respondents received less education, were less
likely to be employed, and were more likely to
be members of low-income households.
Reporting the Evidence
This evidence report addresses nine key
research questions encompassing 49
technologies, including several service-related
interventions. However, the quantity and quality
of published literature was insufficient to permit
an evidence-based evaluation of 39 of these
technologies. We therefore evaluated one
diagnostic technology, three antiepileptic drug
(AED) strategies, five surgical procedures, and
one nondrug, nonsurgical intervention. In
addition, we also surveyed the definitions of
treatment-resistant epilepsy in the published
clinical literature, with particular emphasis on
the definitions reported in clinical studies.
The outcomes we considered depended upon
the key research question. We used 16 patient-
oriented outcomes to evaluate the effects of
treatment, and all reported measures of
diagnostic test performance. We also examined
the rates of all-cause mortality and cause-specific
mortality among persons with epilepsy.
Methodology
To obtain information for this report, we
systematically searched 23 electronic databases,
including PubMed® and EMBASE. In general,
literature searches covered the years 1985 to
January 1, 2002. For topics on AEDs, we
searched for studies published between 1975
and January 1, 2002. We employed these earlier
search dates to ensure that we captured data on
standard drug treatments, which are likely to be
in relatively older literature.
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We employed different search strategies for each of the nine
key research questions. Searches were implemented by first
developing a list of Medical Subject Headings (MeSH) terms,
publication types, and textword combinations. This list
included the concepts inherent in each of the key research
questions. These searches identified 11,111 articles. From
these identified articles, we retrieved 2,356 potentially relevant
articles to determine whether they met the a priori criteria
tailored for each key research question.
Three hundred forty-eight articles met these inclusion
criteria. We next evaluated these articles to determine whether
they contained design flaws so severe that their results were
uninterpretable. Such articles were excluded. In addition, we
excluded articles if there were fewer than five published studies
on a given intervention or diagnostic, and none of the studies
was a randomized controlled trial with 50 or more patients in
the treatment arm. We adopted this latter criterion because of
the difficulty in reaching firm evidence-based conclusions
from a relatively small literature base comprised of studies of
less than optimal design. As a result, 299 articles are included
in this evidence report for key research questions 2-9. One
hundred eighty-five articles for key research question 1 (on
definitions of treatment-resistant epilepsy) were selected from
all of the articles included in key research questions 2-6, from
available clinical guidelines, and from a random sample of 100
review articles.
We employed a “best evidence” synthesis in this evidence
report. Thus, for each key research question, we used the best
available evidence, not the best possible evidence.
Consequently, studies of several designs were included in this
report. Diagnostic case-control studies are the most common
design for diagnostic topics, randomized controlled trials
(RCT) are most commonly used for evaluating AED
strategies, and the surgical literature is comprised almost
exclusively of retrospective case series.
We evaluated the internal validity of all included studies
using checklists of biases that could potentially affect their
results. In considering study design, we assumed that
randomized controlled trials provide results with the least
potential for bias. This was followed, in order of increasing
potential for bias, by controlled studies of other design, studies
that measured patient outcomes before and after some
intervention, and uncontrolled studies. Among each type of
study, we considered blinded studies to have lower potential
for bias than nonblinded studies, and prospective studies to
have lower potential for bias than retrospective studies.
In parts of this report, we used a systematic narrative review
supplemented by numerous de novo calculations. These
include calculations that index the statistical power of
nonsignificant studies, various statistics (e.g., chi-square tests),
crude mortality ratios, and other quantities, as appropriate.
The majority of this evidence report is, however, meta-
analytic.
We performed random effects meta-analyses on data from
RCTs examining polytherapy AED treatment. We used
sensitivity analyses to evaluate how robust the results of these
analyses were. Sensitivity analyses consisted of removing the
largest and smallest studies from the meta-analysis, and
removing the studies with the largest and smallest effects. Each
of the trials in these meta-analyses is an instance of
polytherapy, rather than a direct study of this strategy.
However, combining these trials into a single analysis of
polytherapy can provide an approximate estimate of the effect
of adding a single new AED to patients’ regimens.
We performed threshold analyses on data from
uncontrolled studies of sequential monotherapy and surgery.
For sequential monotherapy, we employed random effects
models, whereas for surgery we employed fixed effects models.
We used random effects models for analyses of sequential
monotherapy because of the heterogeneity among results of
trials using different AEDs. In our threshold analyses, we
meta-analytically compared the improvement rate in treated
patients to increasing rates of improvement in a hypothetical
“control” group. Starting at 0 percent, we increased the rate of
improvement in the “control” patients until the difference in
improvement between the treated and “control” groups was no
longer statistically significant. This value is the threshold.
Where possible, we provide context for these thresholds by
supplementing them with historical data obtained from
published articles.
We also report the percentage of patients who improved
after the intervention (as given by the meta-analytic results
when improvement in the control group is 0 percent), but
note that this percentage is not a measure of the net
effectiveness of the intervention. Some patients may have
improved without treatment. Nevertheless, this percentage is
informative because it represents the proportion of patients
likely to improve, regardless of the cause of their
improvement.
When heterogeneity among study results was found in a
threshold analysis, we attempted to “explain” the source of the
heterogeneity using meta-regression. Because of the lack of
strong a priori hypotheses about the reasons for this
heterogeneity, we constructed multiple meta-regression models
for each instance in which heterogeneity was found. The post
hoc nature of these analyses led us to adopt stringent criteria
for identifying models for further exploration. These




Question 1: What are the definitions of treatment-resistant
epilepsy used in the literature?
• Treatment resistance is infrequently defined in the
literature. Less than one third of the surveyed publications
reported any definition of this term. 
• When treatment resistance was defined, definitions
typically included the number of AEDs a patient tried
before being considered treatment-resistant. Some
definitions also included seizure frequency, duration of
illness, and whether AEDs were administered at maximum
tolerable doses. 
• Drug trials tended to require fewer failures of AED
treatment compared to surgical trials. This is because a very
thorough assessment of drug regimens is usually attempted
before surgery is considered. Assessments are usually less
thorough when giving a patient another AED.
• Despite the fact that reports of clinical trials and review
articles regularly use terms such as “intractable,”
“refractory,” or “treatment-resistant” to describe patients for
whom one or more treatments have failed, no consensus
exists as to precisely what these terms mean.
Question 2: Which methods of rediagnosing or
reevaluating treatment-resistant epilepsy lead to, or can be
expected to lead to improved patient outcomes?
We partitioned this question into four subquestions. The
first two subquestions addressed differential diagnosis of
epileptic seizures from nonepileptic seizures. The remaining
two subquestions addressed the differential diagnosis of
different seizure types. Whether we addressed some questions
depended on the findings for previous questions.
Question 2A: Do all patients diagnosed with epilepsy that is
deemed to be treatment-resistant truly have epilepsy?
This question attempts to gauge the extent of the need for
rediagnosis among patients thought to have treatment-resistant
epilepsy. Our evaluation of the published literature suggests
the following:
• Meta-analysis suggests that up to 35 percent of patients
originally diagnosed with treatment-resistant epilepsy either
do not have epilepsy, or they have a combination of both
epileptic and nonepileptic seizures. Because this number is
derived from studies that enrolled patients suspected of
having nonepileptic seizures, the actual number is probably
lower.
• None of the studies included in the above-mentioned
meta-analysis contained pediatric patients. Thus, the
prevalence of pediatric patients diagnosed with treatment
resistant epilepsy and who either do not have epilepsy or
have a combination of both epileptic and nonepileptic
seizures is unknown.
• These findings suggest that some patients enrolled in
studies included in this evidence Report may not have
epilepsy. If this is the case, then our estimates of the
efficacy of the interventions that we address may be
imprecise.
Question 2B: Which diagnostic modalities are useful in
differentiating seizure types commonly mistaken for epilepsy
from true epileptic seizures?
• A paucity of high-quality evidence limited our ability to
draw evidence-based conclusions about measurement of
serum prolactin levels as a diagnostic tool. Consequently,
we were precluded from developing diagnostic decision-
model algorithms that take into account the realities of
clinical practice, where a differential diagnosis is based on
information from many diagnostic technologies, not just
information from a single diagnostic in isolation.
• The only relevant diagnostic supported by a sufficient
quantity of literature to allow evidence-based analysis was
serum prolactin. The relatively low quality of this
literature, however, precludes firm evidence-based
conclusions. Rather, this literature only allows the
conclusion that serum prolactin levels could plausibly
distinguish epileptic seizures from some nonepileptic
seizures. Further research is required to determine whether
the performance of this test is sufficient to warrant its use
in clinical practice.
• Despite the importance of video-electroencephalography
(vEEG) in diagnostic protocols aimed at differentiating
epileptic seizures from nonepileptic seizures, we do not
draw evidence-based conclusions regarding the diagnostic
performance of this technology in the present report
because less than five high quality studies were identified.
The fact that evidence-based conclusions were not drawn
should not be interpreted as evidence that this technology
is not effective or useful. Indeed, vEEG may very well have
an important role in diagnostic algorithms designed to
differentiate patients with epilepsy from patients with
nonepileptic seizure disorders. Until more high-quality
studies become available, however, the diagnostic
performance characteristics of vEEG and its place in such
diagnostic algorithms cannot be determined.
Question 2C: Is seizure type in patients with treatment-
resistant epilepsy misdiagnosed in some patients?
• There were too few acceptable studies addressing this
question to permit analysis.
Question 2D: Which diagnostic modalities are useful in
differentiating between different seizure types?
Because no evidence-based conclusions could be reached for
Question 2C, the diagnostic modalities that are most useful in
differentiating between different seizure types could not be
determined.
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Question 3: Is there evidence that patients with treatment-
resistant epilepsy are not optimized at their current level of
treatment?
• Not all patients with treatment-resistant epilepsy receive
optimized AED treatment.
• The percentage of patients with treatment-resistant epilepsy
who are not receiving optimized therapy is difficult to
estimate. This is because of a lack of relevant, large,
population-based studies. Further, many studies of AEDs
do not report whether patients comply with their AED
regimens.
Question 4: Which drug treatment strategy, (A) sequential
monotherapy, (B) polytherapy, or (C) optimized current
therapy leads to improved outcomes for patients with
treatment-resistant epilepsy, and (D) what are the relative
improvements obtained with each strategy?
Based on the recommendation of the partners, for the
purposes of this question, sequential monotherapy is defined
as changing a patient’s drug regimen from one or many AEDs
to a single, different AED. Polytherapy is defined as changing
a patient’s drug regimen from one or many AEDs to a
different multiple-AED regimen. In this report, all polytherapy
trials were trials of a single add-on AED. Optimized current
therapy was defined as changing the dose and/or the frequency
of administration. Based on the recommendation of the
partners, we also included the removal of one or more drugs
within this definition.
Question 4A: Sequential monotherapy
• During long-term studies, an estimated 89 percent of
patients continued to have seizures when switched to
monotherapy. The remaining 11 percent of patients were
seizure-free during the studies. When short-term studies
were included, 16 percent of patients were seizure-free.
However, because these data come from studies that
indirectly addressed this issue, whether sequential
monotherapy is directly responsible for these patients
becoming seizure-free cannot be determined.
• An estimated 16 percent of patients experienced a doubling
of monthly seizure frequency during studies of sequential
monotherapy. 
• An estimated 14 percent of patients experienced a doubling
of two-day seizure frequency during studies of sequential
monotherapy.
• Sequential monotherapy required the removal of patients’
prior AEDs, and in some patients the increases in seizure
frequency were likely caused by this removal. Increases may
be more likely in the subset of patients who switched from
multiple AEDs to a single AED, but available data do not
address this possibility.
• These findings suggest that sequential monotherapy is
more likely to increases seizures than to eliminate seizures.
• One cannot determine the side effects (or their rates)
associated with sequential monotherapy because no studies
compared the adverse effects experienced by patients
during sequential monotherapy with the adverse effects
they had been experiencing during their prestudy drug
regimens. Many patients (53 percent to 95 percent)
experienced mild adverse reactions to the new
monotherapy drug.
• An estimated 5 percent of patients exited studies of
sequential monotherapy due to adverse effects.
• The findings listed above are applicable only to the drugs
and doses examined in this report.
• There was insufficient evidence to draw firm conclusions
about the influence of sequential monotherapy on quality
of life, mood, cognitive function, functional status/ability,
ability to return to (or remain in) work, ability to return to
(or remain in) school, ability to hold a driver’s license, or
mortality.
Question 4B: Polytherapy
• Adding certain AEDs to a patient’s drug regimen has
potential advantages and disadvantages. Patients who
receive these add-on drugs are more likely to experience
reductions in seizures compared to patients who receive an
add-on placebo. However, recipients of these drugs are also
more likely to experience adverse effects leading to trial exit
than are placebo recipients (8 percent vs. 4 percent). Many
patients (55 percent to 94 percent) experienced mild
adverse effects while taking the new drugs.
• The preceding estimates of the effect of add-on therapy are
based on random-effects meta-analyses that combined
different AEDs. These estimates serve as approximate
guides for future research on polytherapy. However, their
generalizability may be limited to the drugs and doses in
the included trials. Further, the apparent effectiveness of an
add-on drug may depend on concurrent medications.
Thus, the results may not be applicable to patients
receiving other concurrent medications. Also, the results of
these trials cannot be generalized to other implementations
of the polytherapy strategy (e.g., the addition of two
drugs).
• Insufficient evidence was available to draw firm conclusions
about the influence of polytherapy on quality of life,
mood, cognitive function, functional status/ability, ability
to return to (or remain in) work, ability to return to (or
remain in) school, ability to hold a driver’s license, or
mortality.
Question 4C: Optimized Current Therapy
• Drug reduction may lead to increases in seizure frequency
in at least some patients. Although some patients
experience reduced seizure frequency, these reductions were
likely due to regression to the mean. The only other
explanation is that the withdrawn drugs were somehow
causing seizures. Given that the patients included in these
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studies had been on their baseline AED regimens for some
time, this seems implausible.
• Convincing evidence is lacking to suggest that drug
reduction improves quality of life, mood, cognitive
function, or that it reduces the occurrence of drug related
adverse events. Thus, the available evidence suggests that
implementation of the drug-reduction strategy, at least
with the AEDs considered in this report, may lead to
increases in seizure frequency and provide little benefit.
• Due to limited data, no evidence-based conclusions could
be drawn about optimized current therapy that employed
dose increases or changes in frequency of administration.
Question 4D: Comparing AED Strategies
• No included studies directly compared the three AED
strategies. Because of the different goals of optimized
therapy and the other two AED strategies, these
interventions cannot be compared. Differences in the
severity of disease of patients given polytherapy and
sequential monotherapy preclude quantitative comparison.
However, sequential monotherapy was more likely to be
harmful than to be beneficial. The reverse was true for
polytherapy. These qualitative conclusions suggest that
polytherapy may be clinically preferable to sequential
monotherapy.
Question 5: Which methods of nondrug treatment for
epilepsy after initial treatment failure lead to improved
outcomes for patients with treatment-resistant epilepsy?
Question 5A: Surgical Interventions
Temporal Lobe Surgery
• Threshold analyses of retrospective data suggest that 2 years
after temporal lobe surgery, 55 percent of patients are
completely seizure-free, and 68 percent are free of complex
partial seizures. The retrospective case series design of the
studies reporting these outcomes prevents stating that these
rates are the direct result of surgery, because some patients
may have become seizure-free without surgery. However,
50 percent of similar patients who did not receive surgery
in similarly designed studies would have to be seizure-free
before concluding that surgery did not improve this
outcome. Similarly, 65 percent of similar patients who did
not receive surgery would have to be free of complex
partial seizures before concluding that surgery had no effect
on complex partial seizures. To put these thresholds in
context, published data from one RCT suggest that only 8
percent of patients who do not receive surgery become
seizure-free. This suggests that many patients are seizure-
free because of temporal lobe surgery.
• Meta-analysis did not reveal any relationship between
whether a patient becomes seizure-free after temporal lobe
surgery and the patient’s age at surgery, age at seizure onset,
side of surgery, or the presence of simple partial seizures.
Larger studies are required to prove that there is no
relationship between these patient characteristics and the
outcome of surgery.
• The rate of new cases of depression after surgery ranges
from 4 percent to 24 percent. Why this range is so wide is
not clear, and whether surgery was responsible for these
new cases cannot be determined. 
• Threshold analysis suggests that 3 percent of patients
develop psychosis after surgery. However, data from one
trial with similar patients who did not receive surgery
suggest that as many as 2 percent of these patients develop
psychosis. Two percent is also the threshold at which a
relationship between surgery and the onset of psychosis
becomes statistically nonsignificant. Therefore, surgery
cannot be assumed responsible for new cases of psychosis.
• Threshold analysis suggests that after temporal lobe
surgery, approximately 13 percent of patients experience
clinically significant increases in IQ and 10 percent of
patients experience clinically significant decreases in IQ.
The threshold analysis suggests that surgery may not be
responsible for these changes if 10 percent of similar
patients who did not receive surgery experienced an
increase in IQ, and 7 percent of similar patients who did
not receive surgery experienced a decrease in IQ. Data
from one trial suggest that without surgery, 5 percent of
patients experience a decrease and 5 percent of patients
experience an increase in IQ. Therefore, if there is an effect
of surgery on IQ, it does not affect large numbers of
patients.
• Approximately 2 percent of patients will experience
permanent complications from temporal lobe surgery,
primarily some form of partial paralysis. Data reported in
studies of temporal lobe surgery reporting deaths due to
surgery suggest that approximately 0.24 percent of patients
will die because of the surgical procedure.
• There was insufficient evidence to draw firm conclusions
about the influence of temporal lobe surgery on quality of
life, memory, functional status or ability, ability to return
to (or remain in) work, ability to return to (or remain in)
school, or ability to hold a driver’s license.
Corpus Callosotomy
• Threshold analyses suggest that 2 years after corpus
callosotomy, 20 percent of patients have achieved a 90
percent or better reduction in overall seizure frequency.
The retrospective case series design of the studies reporting
this outcome prevents stating that these rates are the direct
result of surgery, because some patients may achieve a 90
percent reduction in seizure frequency without surgery.
However, 15 percent of similar patients who did not
receive surgery would have to experience a 90 percent or
better reduction before concluding that surgery did not
improve this outcome. No studies were available to provide
context for these figures. Given the severity of patients’
conditions, however, surgery is the most likely cause of
these seizure reductions.
• Despite the improvements seen in some patients, 16
percent of patients will achieve no reduction in overall
seizure frequency or show an increase in seizure frequency
after corpus callosotomy.
• Threshold analysis suggests that 2 years after corpus
callosotomy, 26 percent of patients will be free of their
most disabling seizures. However, 20 percent of similar
patients who did not receive surgery would have to become
free of their most disabling seizures before concluding that
surgery did not improve this outcome. No studies were
available to provide context for these figures. Given the
severity of patients’ conditions, however, surgery is the
most likely cause of these seizure reductions.
• Approximately 3.6 percent of patients will experience
serious complications after corpus callosotomy, primarily
some form of partial paralysis, disconnection syndrome, or
language difficulty. The precise mortality rate associated
with this procedure is uncertain.
• There was insufficient evidence to draw firm conclusions
about the influence of corpus callosotomy on quality of
life, mood, cognitive function, functional status/ability,
ability to return to (or remain in) work, ability to return to
(or remain in) school, or ability to hold a driver’s license.
Frontal Lobe Surgery
• Studies of frontal lobe surgery report that 2 years after
surgery, 20 percent to 100 percent of patients will be
“seizure-free” depending on how this outcome is defined.
These variations in outcome reporting prevented any
meaningful threshold analysis.
• Approximately 8.4 percent of patients will experience some
type of complication after frontal lobe surgery, primarily
some form of partial paralysis. However, this figure may be
inaccurate because only two studies reported
complications. Data reported in three studies of frontal
lobe surgery reported only one death among 96 patients.
These data are insufficient to estimate the true death rate
from this type of surgery.
• There was insufficient evidence to draw firm conclusions
about the influence of frontal lobe surgery on quality of
life, mood, cognitive function, functional status/ability,
ability to return to (or remain in) work, ability to return to
(or remain in) school, or ability to hold a driver’s license.
Hemispherectomy
• Three studies reported that between 40 percent and 70
percent of patients who receive hemispherectomy are
seizure-free 2 years after surgery. Approximately 7 percent
of patients may receive no benefit from this surgery. The
paucity of literature on this topic means that these rates are
not precise. Given the severity of patients’ conditions,
however, surgery is the most likely cause of this
improvement.
• Ten studies reported only two serious permanent
complications from surgery (0.8 percent). However, given
the small number of patients examined in these 10 studies,
this may not be a reliable estimate. Among the same
studies, the percentage of patients developing a mild or
transient complication was 21 percent. Data reported in 11
studies of hemispherectomy suggest that approximately 2.6
percent of patients (26 deaths per 1,000 patients) will die
because of the surgical procedure.
• There was insufficient evidence to draw firm conclusions
about the influence of hemispherectomy on quality of life,
mood, cognitive function, functional status/ability, ability
to return to (or remain in) work, or ability to return to (or
remain in) school.
Multiple Subpial Transection
• Reported percentages of patients who are seizure-free six or
more months after multiple subpial transection vary from 0
percent to 75 percent, depending on how “seizure-free” is
defined. Similarly, the estimates for patients who do not
benefit from this surgery vary from 0 percent to 42
percent. Consequently, the data are inconsistent across
studies and do not allow for firm evidence-based
conclusions as to the exact proportion of patients who will
become seizure-free or who will not benefit from multiple
subpial transection.
• Nine studies reporting serious permanent complications
from surgery estimated that approximately 5.9 percent of
patients experience these types of complications,
particularly aphasia or dysphasia. Although no deaths were
reported in any of these studies, they may be reported in
future studies.
• There was insufficient evidence to draw firm conclusions
about the influence of multiple subpial transection on
quality of life, mood, cognitive function, functional
status/ability, ability to return to (or remain in) work,
ability to return to (or remain in) school, or ability to hold
a driver’s license.
Other Surgery
• Too few studies were available to allow for an evidence-
based evaluation of parietal or occipital lobe surgery.
Question 5B: Nondrug, Nonsurgical Interventions
• Trends from two RCTs suggest that vagal nerve stimulation
(VNS), when applied as an adjunct intervention, safely
provides limited seizure frequency reduction in some
patients with treatment-resistant epilepsy. The precise
degree of seizure reduction depends upon the specific
measure of seizure frequency.
• Currently available evidence does not suggest a dramatic
effect of VNS on quality of life.
• There was insufficient evidence to draw firm conclusions
about the influence of VNS on mood, cognitive function,
functional status/ability, ability to return to (or remain in)
work, ability to return to (or remain in) school, or ability
to hold a driver’s license.
• Too few studies were available to allow for an evidence-
based evaluation of ketogenic diets, chiropractic
6
7
procedures, acupuncture, hyperbaric oxygen therapy, herbal
medicine and homeopathy, cranial realignment, magnetic
therapy, electrical brain stimulation, and vitamin B6
therapy.
Question 6: Which social, psychological or psychiatric
services for treatment-resistant epilepsy lead to, or can be
expected to lead to improved patient outcomes?
• There were too few acceptable studies addressing this
question to permit analysis.
Question 7: What characteristics of treatment-resistant
epilepsy interfere with ability to obtain and maintain
employment, or attend and perform well in school?
• There were too few acceptable studies addressing this
question to permit analysis.
Question 8: What is the mortality rate of patients with
treatment-resistant epilepsy?
• Persons with treatment-resistant epilepsy are approximately
2 to 10 times more likely to die compared to people in the
general population. This excess mortality in persons with
treatment-resistant epilepsy is largest among younger
individuals. 
• Sudden unexpected death appears to be a major cause of
death among patients with treatment-resistant epilepsy,
representing 6 percent to 55 percent of the total deaths in
studies that reported relevant data.
• Drowning rates are higher among treatment-resistant
patients with epilepsy compared to the general population.
Higher quality evidence is needed to determine the precise
magnitude of the difference in drowning rates.
• There is insufficient evidence to determine whether
accident-related mortality, or mortality due to pneumonia,
aspiration, suicide or cancer is higher among persons with
epilepsy compared to the general population.
Question 9: Is there a correlation between the number
and/or type of seizure and sudden death?
• Generalized tonic-clonic seizures appear to increase the risk
of sudden death.
• The relationship between overall seizure frequency and
sudden death is uncertain.
Future Research
Our analysis suggests that at least some patients receiving
treatment for epilepsy either do not have epilepsy or have
another condition in addition to epilepsy that also causes
seizures or seizure-like events. Studies that clearly describe the
diagnostic procedures used to confirm that patients actually
have epilepsy are needed and would present a more accurate
assessment of the efficacy of the treatment under study. Our
analysis also suggests that some patients receive AEDs at less
than the maximum tolerable dose. Future studies could ensure
that patients are truly treatment-resistant by enrolling only
subjects who are optimized and compliant with their current
therapy. 
In the absence of a control group, the effects of treatment
cannot be differentiated from placebo effects, regression to the
mean, extraneous events, or other threats to internal validity.
Although there are situations in which controlled trials are
impractical, controlled trials are needed to provide a more
accurate picture of the effects of treatment.
Studies with inadequate numbers of patients cannot detect
clinically meaningful differences in outcomes between
treatment groups. When designing clinical trials, a priori
power analysis calculations can be used as a guide to ensure
that sufficient numbers of patients are enrolled so that the
proposed trial can uncover clinically meaningful relationships
between treatments and outcomes.
Many publications do not contain sufficient information to
enable the reader to accurately judge the evidence. Some
confusion could be alleviated if seizure-free outcome
measurements were standardized. A well-reported trial would
include seizure frequency as well as a measure of data
dispersion, both at baseline and at several followup periods.
Studies of diagnostics
The lack of an accepted gold standard for the differential
diagnosis of epileptic seizures from nonepileptic seizures makes
evaluating the utility of any given diagnostic problematic. This
is because of the difficulty in verifying that the diagnostic
decisions that result from the use of the test are correct. Given
this lack of an acceptable gold standard, attempting to
determine whether the use of a diagnostic improves patient
outcomes may offer a fruitful avenue for future research. Such
an approach requires determining whether the use of the
diagnostic of interest ultimately leads to improved patient
outcomes and, as a consequence, requires a prospective,
randomized controlled trial.
Because a diagnosis of epilepsy is not made based on the
findings of a single diagnostic technology, studies are needed
to evaluate the effectiveness of different clinical algorithms that
utilize data collected from combinations of diagnostic
technologies. Again, this approach would require a prospective,
randomized controlled trial.
Studies of treatment
In the literature on drug strategies, an important direction
for future research involves direct comparisons between the
drug strategies for treatment-resistant epilepsy. None of the
studies included in our assessment of drug strategies made
direct comparisons between sequential monotherapy and
polytherapy. Ideally, a trial would randomize patients to
different drug strategies, and compare seizure frequency
outcomes as well as adverse effects of treatment.
Another area for future research on drugs concerns the
adverse effects patients experience from their pretrial drug
regimens and changes in these adverse effects on the new
treatment regime. Changes in the frequency and severity of the
adverse effects associated with each drug treatment strategy
need to be evaluated, because patients and clinicians seek to
reduce adverse effects as well as seizure frequency.
Prospective studies of surgical interventions are needed. This
approach would allow seizure and nonseizure-related outcome
measures to be recorded at multiple followup periods (1 year, 2
year, 5 year, etc.) rather than the single mean or median
followup reported in most retrospective studies. Better
reporting of patient characteristics is also needed and, if
possible, individual patient characteristics should be reported
when study sizes are small (less than 20 patients). Studies
reporting standardized quality of life measures, validated for
patients with epilepsy, would help in determining the effect of
surgery on this important nonseizure-related outcome. Studies
reporting other types of nonseizure-related outcome measures,
such as employment, education, and cognitive function data,
are also needed.
Higher quality controlled trials are particularly lacking for
the nonmedical treatments such as education and training in
skills that may help prevent seizures or enable patients to
better adapt to seizures. This area constitutes another
important direction for future research.
Studies of patient characteristics related to
employment and school
Reporting of employment and schooling status among
patients with treatment-resistant epilepsy is particularly lacking
in both the medical and nonmedical treatment literature. The
ideal study design to address this question would be a
prospective cohort study using multiple regression techniques
to evaluate the potential correlation between specific patient
characteristics and the ability to work or attend school both
before and after treatment. This is an area in particular need of
future research and higher quality studies.
Studies of mortality
The present literature has a number of large (mostly
retrospective) studies that have calculated standardized
mortality rates (SMRs) for overall mortality, but few studies
have calculated separate SMRs for specific causes of death or
subgroups of specific ages. To generate meaningful data,
cohort studies must enroll sufficient numbers of patients and
follow the patients for sufficient periods. The most useful
study of mortality among patients with treatment-resistant
epilepsy would be a large prospective study that followed
patients for several years. In addition to calculating an SMR
for overall mortality, the study would calculate SMRs for
specific causes of death, especially those that could be related
to epilepsy (such as accidents, drowning, and motor vehicle
accidents). 
Large prospective studies where all suspected sudden
unexpected death in epilepsy (SUDEP) cases receive an
autopsy are needed. An autopsy is particularly important
because it provides the best evidence that the death did not
have an explainable cause. This would increase the accuracy of
estimates of SUDEP rates for different age subgroups of
patients with treatment-resistant epilepsy.
More prospective case-control studies using multiple
regression analysis would be useful to address the potential
relationship between SUDEP and seizure type or frequency.
Future studies would ideally include a hundred patients or
more to ensure that there is adequate statistical power to detect
correlations. Multiple regression analysis is needed to reduce
the effect of possible confounding variables and increase the
likelihood that an observed statistically significant correlation
represents an actual causal relationship.
Availability of the Full Report
The full evidence report from which this summary was
taken was prepared for the Agency for Healthcare Research
and Quality (AHRQ) by the ECRI Evidence-based Practice
Center, under Contract No. 290-97-0020. It is expected to be
available in May 2003. At that time, printed copies may be
obtained free of charge from the AHRQ Publications
Clearinghouse by calling 800-358-9295. Requesters should ask
for Evidence Report/Technology Assessment No. 77,
Management of Treatment-Resistant Epilepsy. In addition,
Internet users will be able to access the report and this
summary online through AHRQ’s Web site at www.ahrq.gov.
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